IL-33 Inhibitor Delivers in COPD Trials

(MedPage Today) -- A broad population of people with chronic obstructive pulmonary disease (COPD), current and former smokers alike, experienced fewer exacerbations taking a first-in-class biologic targeting interleukin (IL)-33, a pair of double...